Project Update: Kinetics for Drug Discovery (K4DD)

‘We brought target binding kinetics to the international research community’ – an interview with the K4DD project coordinators

The Kinetics for Drug Discovery project which stated in late 2012 and involved investment from the public and private sector of over €20 million Euros was completed in the 2017.

The partnership was coordinated by Bayer with 20 partners from 6 countries (including the University of Dundee) and was created with a vision ‘to enable the adoption of drug-target binding kinetics analysis in the drug discovery decision–making process, and thereby contribute to the development of a new generation of improved medical products’

The result of the investment and collaborative approach has been reported in the latest IMI newsletter as having ‘transformed the field, improving the understanding of how potential drugs bind with their target. It also developed methods and tools to allow researchers to study drug-target interactions with greater ease’

In the interview with the project officer and the coordinator Anke Mueller-Fahrnow of Bayer, and academic coordinator Ad IJzerman of Leiden University explain how the project transformed the field and could lead to more effective drugs in the future.

‘Thanks to K4DD, more and more scientists within pharma companies but also in academia are aware of the importance of binding kinetics,’ said Mueller-Fahrnow. ‘So something that has really been pretty exciting and novel ten years ago, is something that is now broadly appreciated and used in the drug discovery process.’

The K4DD project website reports that even though the project has officially ended, the impact of the project still continues to resonate. After the end of the project K4DD has published an impressive amount of publications in High Impact journals such as multiple in Scientific Reports, Angewandte Chemie and  Nature Communications. The current number of K4DD publication is well over 50, however several manuscripts are still in the pipeline and we expect to see more K4DD output throughout the rest of 2018.

The K4DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115366], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution

Richard Buxbaum - Scotland Europa - NCP Services
SME Innovation
Health, Well-being and Life Sciences